Next Article in Journal
Research on the Relationship between Reaction Ability and Mental State for Online Assessment of Driving Fatigue
Previous Article in Journal
Ecosystem Services Insights into Water Resources Management in China: A Case of Xi’an City
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 13
Issue 12
10.3390/ijerph13121177
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study

by
Pilar Carrasco-Garrido
*,
Valentín Hernández-Barrera
,
Isabel Jiménez-Trujillo
,
Jesús Esteban-Hernández
,
Alejandro Álvaro-Meca
,
Ana López-de Andrés
,
José Luis DelBarrio-Fernández
and
Rodrigo Jiménez-García
Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University, Alcorcón 28922, Spain
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2016, 13(12), 1177; https://doi.org/10.3390/ijerph13121177
Submission received: 9 October 2016 / Revised: 10 November 2016 / Accepted: 22 November 2016 / Published: 24 November 2016
(This article belongs to the Section Global Health)
Versions Notes

Abstract

:
Background: We performed an epidemiologic study to analyze nationwide time trends in adult psychotropic drug use over a period from 2006 to 2012, and to identify those factors associated with the likelihood of consumption of these drugs during the study period; Methods: Cross-sectional study on psychotropic medication in the Spanish adult population. We used secondary individualized data drawn from the 2006 and 2012 Spanish National Health Surveys (SNHS). The dependent variable was the use of psychotropic drugs in the previous two weeks. Independent variables included socio-demographic characteristics, comorbidity, lifestyles and healthcare resource utilization. Using logistic multivariate regression models, we analyzed the temporal evolution of psychotropic medication consumption between 2006 and 2012 in both sexes; Results: The prevalence of psychotropic drug use was significantly greater in women (18.14% vs. 8.08% in 2012 (p < 0.05). In Spanish women, the variables associated with a greater probability of psychotropic use were, age, unemployment (adjusted odds ratio (AOR), 1.60; 95% CI, 1.24–2.07), negative perception of health or taking non-psychotropic drugs. Among men, psychotropic use is associated with presence of chronic disease, negative perception of health (AOR, 3.27; 95% CI, 2.62–4.07 in 2012) or inactive status; Conclusions: Between 2006 and 2012, the probability of having taken psychotropic drugs increased by 16% among women. Unemployed women aged ≥45 years with a negative perception of their health constitute a clear risk profile in terms of psychotropic drug use. Inactive men who have a negative perception of their health are the group most likely to consume psychotropic drugs.

1. Introduction

Health is affected by a series of determinants including socioeconomic conditions, working and living conditions, and social gradient [1]. In recent years, research on inequality in healthcare shows that morbidity and mortality are higher in people with a lower socioeconomic level than in those with a higher socioeconomic level [2,3].
Several studies have examined the effect of socioeconomic factors on mental health [4,5,6,7]. If we take into account educational level, occupational status, and income, it seems reasonable to suppose that these same factors could play a role in the effects of pharmacologic and psychosocial interventions and lead to social inequality in the response to treatment of psychiatric diseases [8,9].
Patients diagnosed with mental health problems are often prescribed a psychotropic drug (anxiolytics, antidepressants, or hypnotics-sedatives) [10,11,12]. According to the results for Spain in the European Study of the Epidemiology of Mental Disorders (ESEMeD) [13], 16% of the Spanish population reported having taken at least one psychotropic drug during the previous year. However, recent research has revealed that a high proportion of individuals with mental health disorders have not received an appropriate diagnosis or treatment. In fact, the results of some of these studies, such as that performed by the National Comorbidity Survey Replication (NCS-R), show that 58.1% of people with a depressive disorder have not visited a health center to obtain treatment for their problem [14].
In Spain, psychotropic drugs are available only by prescription. The scientific literature provides sufficient evidence that the prescription of a psychotropic drug is affected by various clinical and non-clinical factors (e.g., patient characteristics such as age and sex [15] and socioeconomic factors such as profession and social class [12]). Considering that consumption may be affected by adverse socioeconomic contexts, it is relevant to determine whether there have been any changes in the rate of consumption of psychotropic drugs in Spain during the recent period of instability [5], in comparison with the time before this situation arose [13].
In this context, we performed an epidemiologic study to analyze nationwide time trends in adult psychotropic drug use over a period from 2006 to 2012, and to identify those factors associated with the likelihood of consumption of these drugs during the study period.

2. Materials and Methods

We used individualized secondary data retrieved from the 2006 and 2012 Spanish National Health Surveys (SNHS) to conduct a nationwide, cross-sectional study on psychotropic drug use in individuals aged ≥25 years in Spain. SNHS are interview-based surveys undertaken by the Ministry of Health and Consumer Affairs that target a large sample of the non-institutionalized population in Spain. The surveys use multistage cluster sampling, with proportional random selection of primary and secondary sampling units (towns and sections, respectively); the final units (individuals) are selected using random routes and sex- and age-based quotas. The 2006 survey included 29,478 adults of both sexes interviewed between June 2006 and June 2007; the 2012 survey included 20,007 persons interviewed from July 2011 to June 2012. Details of National Health Survey methodology are reported elsewhere [16,17]. The variables included in our study were selected on the basis of a series of identically worded questions asked in the two surveys used.
The study population comprised people of both sexes aged ≥25 years. The study was based on 46,661 surveys, as follows: 27,310 from SNHS 2006 and 19,351 from SNSH 2012. The dichotomous dependent variables chosen were the answers “yes” or “no” to the question “In the last two weeks have you taken the following medicines and were they prescribed for you by a doctor?” with two possible answers: (1) tranquilizers (anxiolytics) or sedatives (anxiolytics) or sleeping pills (anxiolytics), and (2) antidepressants. The independent variables are the primary sociodemographic characteristics of the population, namely, age, sex, occupational status, educational level, total monthly household income in euros, and social class. The lifestyle-related variables were currently smoking (yes/no), consumption of any alcoholic beverages in the two weeks prior to the survey (yes/no), leisure time physical activity in the last week (intense or moderate vs. none), and self-reported body mass index (categorized as <25, 25–30, and >30). In order to assess the use of healthcare resources, respondents were asked about visits to a primary care physician (medical consultation in the preceding four weeks (yes/no)) and whether they had taken any type of medication, excluding psychotropic drugs, in the last two weeks. Self-reported presence of any chronic disease and self-rated health status (excellent/very good vs. fair/bad/very bad) were analyzed as dichotomous variables.

2.1. Ethical Statements

In accordance with Spanish legislation, there is no need for Ethics Committee approval, since the database was obtained from the Spanish Ministry of Health, Social Services and Equality webpage, where it is publicly available. The data was provided to us and therefore analyzed anonymously.

2.2. Statistical Analysis

We calculated the prevalence of psychotropic drug use for each of the two surveys according to the study variables. Pearson’s χ2 test was used for the bivariate comparison of proportions, and statistical significance was set at a p value < 0.05 (two-tailed). To estimate the independent effect of each of the study variables on the consumption of psychotropic drugs, we also obtained the corresponding adjusted odds ratio (AOR) using multivariate logistic regression analysis. Two models were generated, one for women and another for men.
Finally, to assess the time trend in the consumption of psychotropic drugs over the period 2006–2012, we combined the respective databases of the two SNHS and calculated the crude and adjusted odds ratios (crude odds ratio (COR) and AOR) for having consumed the psychotropic drug in 2012 compared with 2006, for both sexes. For calculation of the adjusted OR, all variables that proved to be predictive in either of the SNHS were included in the multivariate logistic regression.
Estimates were made using the “svy” function (survey command) of the STATA program (STATA Corp, College Station, TX, USA), which enabled us to incorporate the sampling design and weights into all statistical calculations (descriptive, χ2, and logistic regression). Statistical significance was established as a two-tailed α < 0.05.

3. Results

Our results showed that 16.79% of adults aged ≥25 years and interviewed in 2006 and 15.58% in the year 2012 reported having taken a psychotropic drug during the two weeks preceding the survey. Table 1 shows the frequency of psychotropic drug use (anxiolytics and antidepressants) in both sexes during the study period. The frequency of anxiolytic use increased in both sexes in 2012.
Data on psychotropic drug use in both sexes according to sociodemographic characteristics, lifestyle, and health-related study variables are shown in Table 2.
The prevalence of psychotropic drug use was significantly greater in women (18.14% (17.30–19.02) vs. 8.08% (7.43–8.78)) in 2012 for all the categories of variable analyzed and during the years 2006 and 2012 (p < 0.05). Psychotropic drug use was significantly more frequent in individuals with no formal schooling, unemployed people, and inactive people, especially women. Similarly, in both surveys, men and women with a negative perception of their health took more psychotropic drugs than persons with a good perception of their health (37% vs. 1.9% in women and 20.2% vs. 3.9% in men for the year 2012; p < 0.05).
The multivariate logistic regression analysis (Table 3) revealed the independent effect of each of the study variables (adjusted for the others) on psychotropic drug use in our sample for both sexes and during the years analyzed.
Analysis of patterns of use among women revealed that the variables that were independently and significantly associated with a greater probability of psychotropic drug use were age (particularly in the 45–64-year-old group in 2012 (AOR, 1.89; 95% CI, 1.55–2.30)) and occupational status (people who were unemployed in the SNHS 2012 (AOR, 1.60; 95% CI, 1.24–2.07) and inactive in the SNHS 2006 (AOR, 1.19; 95% CI, 1.01–1.42 and the SNHS 2012 (AOR, 1.88; 95% CI, 1.51–2.33)). The variables with the highest values of association among women in both 2006 and 2012 were negative perception of health (SNHS 2006, AOR, 3.63 (95% CI, 3.15–4.18); SNHS 2012, AOR, 3.60 (95% CI, 3.12–4.17)) and taking non-psychotropic drugs.
As for Spanish men, the health profile analysis showed that the presence of chronic disease, medical consultation, and negative perception of health were all likewise significantly associated with more frequent psychotropic drug use (SNHS 2006, AOR, 3.84 (95% CI, 3.07–4.80); SNHS 2012, AOR, 3.27 (95% CI, 2.62–4.07)). In both surveys, we found that inactive men were more likely to use psychotropic drugs (SNHS 2006 AOR, 2.96; 95% CI, 2.15–4.00; SNHS 2012 AOR, 1.88; 95% CI, 2.02–4.00).
To assess the time trend in the consumption of psychotropic drugs over the period 2006–2012, and taking 2012 as reference for having a higher consumption, analysis of the trend in psychotropic drug consumption from 2006 to 2012 in Spanish women, yielded a COR of 0.91 (95% CI, 0.84–0.90). On controlling for possible confounding variables, this statistical significance was maintained (AOR, 1.16; 95% CI, 1.06–1.28), meaning that in 2012 psychotropic drug consumption in women was 16% greater than that reported in 2006. Changes in trends of psychotropic drug consumption among Spanish men during the study period were not statistically significant.

4. Discussion

Our results show that the prevalence of prescription psychotropic drug use by Spanish adults reached 16.79% in 2006 and 15.58% in 2012. These values are lower than the 33.6% reported in a recent study on psychotropic drug prescription patterns in primary health centers [10], although they are higher than those found in other developed countries, such as the 5.92% reported by Athanasopoulos et al. in Greece based on a survey carried out by the National Center for Social Research [18], the 7.2% reported in the PATH Through Life Study in Australians of the same age group as those we studied [8], and the 8.6% reported by Ilyas et al. [19] for prescription of psychotropic drugs in England.
During the six-year study period, psychotropic drug use in Spain decreased by 1.21%. Use of antidepressants in particular decreased in 2012, in contrast to the results obtained by various researchers from several countries who reported a significant increase in prescription of psychotropic drugs during the last decade [9,20,21,22,23]. However, use of anxiolytics increased to 24.3%, consistent with the results obtained in an ecological study based on Spanish pharmacy dispensing data [24] and with those of Tsimtsiou et al. [12], who determined predictors of prescription of anxiolytics and hypnotics by general practitioners in England based on data from the UK Quality and Outcomes Framework. This increase in the consumption of anxiolytics could be because this drug class is used to treat a wide variety of conditions, whereas antidepressants are indicated for specific conditions.
Despite a 1.21% general decrease in the consumption of psychotropic drugs in Spain during the six years of our study, mainly due to a decline in antidepressant consumption, we must bear in mind that we could be facing a situation of under-declaration of drug consumption. In fact, there are studies, including some from our own country [10], that indicate an increase in consumption in recent years.
Being asked about antidepressant use may still spark socially conditioned responses from some people in Spain due to the negative connotations attached to their consumption. On the other hand, anxiolytic drug consumption may be considered more acceptable and so people may be less reluctant to admit taking this kind of medication. We can only speculate whether anxiolytic and hypnotic drugs are sometimes prescribed in order to counteract some of the side effects of antidepressive drug consumption such as restlessness, anxiety, and problems sleeping. Anxiolytics and hypnotics present addictive properties, which complicate cessation of these drugs for long-term users. Long-term variations in the prevalence of anxiolytic and hypnotic use probably reflect changes of some prescriptions from routine to PRN (pro re nata), or vice versa.
However, it should be noted that when these drug consumption trends are analyzed by gender, we observe a 16% increase among Spanish women, but no changes among men. For decades, the higher prescription and consumption of psychotropic drugs among women has been explained by a greater frequency of affective disorders in women or by their greater vulnerability in our society. This could be due to an increased predisposition among women to recognize and express their symptomatology and to seek medical assistance more frequently.
Sex differences in prescription and use of medications are well documented in the literature, and several variables have been shown to affect prescribing decisions and the outcome of treatment [18,23]. Nevertheless, despite the large body of scientific evidence, the problem remains. In the case of psychotropic drugs, a common denominator in these studies was that women consumed more psychotropic drugs than men [21,22], regardless of whether the patients were young or elderly women [15] or of the degree of social deprivation [9,11].
Our data revealed that Spanish women consume more psychotropic drugs than men, a trend which increased by 16% between 2006 and 2012 (AOR, 1.16; 95% CI, 1.06–1.28). In socioeconomic terms, the typical patient taking psychotropic drugs is a woman aged ≥45 years. A significant association has been found between this profile and psychotropic drug use, consistent with findings from studies such as the Baltimore Epidemiologic Catchment Area (ECA) Study [25], which shows ≥45 years to be the age group with the highest prevalence of behavioral disorders in women, or the Swedish Women’s Health in Lund Area Study (WHILA) (Study [26], which was performed to determine the prevalence of psychotropic drug use in middle-aged women and to examine the association with various social factors and health profiles.
From an occupational viewpoint and consistent with the greater incidence of female unemployment in recent years, Spanish women who were unemployed or inactive in 2012 (AOR, 1.60; 95% CI, 1.24–2.07), were more likely to consume psychotropic drugs than women who were employed. However, in the case of men, we found that inactive men consumed almost three times more psychotropic drugs than those who were employed (AOR, 2.85; 95% CI, 2.02–4.00). Researchers point out that the mental health of people who are unemployed is poorer than that of people who are employed [6,7]. It has also been suggested that sex differences in the effect of unemployment on mental health are associated with differences in the positions and roles of men and women in society and family and that these roles are associated with differences in the psychosocial and financial need for employment [27].
Unemployed men and women may seek professional care for mental health problems more frequently than might be expected, as shown in studies that support the hypothesis of “medicalization of unemployment”, that is, the use of healthcare not only as a response to mental health problems, but also as a way of dealing with unemployment [28]. However, between 2006 and 2012, psychotropic drug use decreased from 9.9% to 5.8% in men and increased from 13.7% to 14.9% in women.
Similarly, we could argue that prescription of psychotropic drugs in our study also seems to be associated with the number of visits to the doctor in both men and women.
Our analysis of variables associated with comorbidity and health-related behavior revealed that chronic diseases and smoking were predictors of psychotropic drug use by Spanish women. Female smokers in Spain are more likely to use psychotropic drugs than non-smoking women. Certain drugs are commonly consumed by smokers, and there is a close relationship between tobacco smoking and psychiatric disorders (a higher proportion of individuals with mental health conditions smoke compared with the general population). We also found a negative association between consumption of alcoholic beverages and the use of psychotropic drugs in both men and women in the two surveys. This finding could be interpreted as appropriate adherence by the patient to the advice of and regimen recommended by the physician when a psychotropic drug is prescribed, although we must remember that affective disorders, especially in men, are very often hidden by behavioral alterations or alcoholism.
Of note, concomitant use of non-psychotropic drugs was one of the variables most closely associated with psychotropic drug use by women (AOR, 3.00; 95% CI, 2.48–3.64). This finding is consistent with data from the annual Health Survey for England 2013, which found that 24% of women reported having taken at least three prescription drugs during the year [29].
We found that a considerable percentage of men and women reported being in poor health and that there was a significant association between men and women with a negative perception of their health and consumption of prescription psychotropic drugs (up to three-fold greater probability of consuming psychotropic drugs than persons with a positive perception of their health). Our results agree with those of several authors in that they reveal negative perception of health to be a predictor of psychotropic drug use, as shown in the results of a recent study carried out in Finland, where psychotropic drug use was almost double among people who had a poorer perception of their health (AOR, 1.90; 95% CI, 1.01–3.68) [30].
The main strengths of our study are its use of a representative sample to assess the prevalence of psychotropic drug use in Spanish adults during the period 2006–2012 and our ability to control for a broad range of major covariates, including socioeconomic factors and health-related variables.
Our study is limited by the nature of national health surveys. First, as the SNHS has not been validated for drug use, it is difficult to generalize the conclusions drawn from the results. Second, national health surveys are based on self-reported data, with the result that the prevalence of psychotropic drug use may be underestimated. Third, some replies may be socially conditioned (owing to the sociocultural association between psychotropic drug use and mental health problems), thus potentially affecting the demand for prescriptions of these drugs. Fourth, the Spanish National Health Survey, rather than identifying specific active pharmaceutical ingredients, identifies groups of medicines for specific diseases, conditions or disorders. Lastly, given that the initial response rate to the SNHS 2006 was 65% and the initial response rate to the SNHS 2012 was 61%, the possibility of a non-response bias must be taken into consideration [16,17].

5. Conclusions

Between 2006 and 2012, the probability of having taken psychotropic drugs increased by 16% in Spanish women. Our results confirm that unemployed women aged >45 years with a negative perception of their health constitute a clear risk profile in terms of psychotropic drug use.
Unemployed men who have a negative perception of their health are the group most likely to consume psychotropic drugs. No increase in consumption was observed in this group during the study period.
The increase in psychotropic drug use by women could be associated with an increased frequency of anxiety disorders. While abundant data can be found on social and cultural causes and on prescription and suitability of treatment, the importance of work-related factors has not received sufficient attention.

Acknowledgments

This study was funded by the FIS (Fondo de Investigaciones Sanitarias—Health Research Fund, grant No. PI13/00369, Instituto de Salud Carlos III) co-financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Pilar Carrasco-Garrido and Rodrigo Jiménez-García originated and designed the study and coordinated the writing of the article. Valentín Hernández-Barrera contributed to the analysis of the data and to the drafting of the paper. Ana López-de Andrés, Jesús Esteban-Hernández, Alejandro Álvaro-Meca, José Luis DelBarrio-Fernández and Isabel Jiménez-Trujillo contributed to the interpretation of the results and to the drafting of the paper. All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors have seen and approved the final version. Pilar Carrasco-Garrido is the guarantor.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Marmot, M. Review of Social Determinants and the Health Divide in the WHO European Region. Final Report. Available online: http://www.euro.who.int/en/health-topics/health-policy/health-2020-the-european-policy-for-health-and-well-being/publications/2013/review-of-social-determinants-and-the-health-divide-in-the-who-european-region.-final-report (accessed on 18 April 2015).
  2. Isaacs, S.L.; Schroeder, S.A. Class: The ignored determinant of the nation’s health. N. Engl. J. Med. 2004, 351, 1137–1142. [Google Scholar] [CrossRef] [PubMed]
  3. Borrell, C.; Azlor, E.; Rodríguez-Sanz, M.; Puigpinós, R.; Cano-Serral, G.; Pasarín, M.I.; Martínez, J.M.; Benach, J.; Muntaner, C. Trends in socioeconomic mortality inequalities in a southern European urban setting at the turn of the 21st century. J. Epidemiol. Community Health 2008, 62, 258–266. [Google Scholar] [CrossRef] [PubMed]
  4. Karanikolos, M.; Mladovsky, P.; Cylus, J.; Thomson, S.; Basu, S.; Stuckler, D.; Mackenbach, J.P.; McKee, M. Financial crisis, austerity, and health in Europe. Lancet 2013, 381, 1323–1331. [Google Scholar] [CrossRef]
  5. Gili, M.; Roca, M.; Basu, S.; McKee, M.; Stuckler, D. The mental health risks of economic crisis in Spain: Evidence from primary care centres, 2006 and 2010. Eur. J. Public Health 2013, 23, 103–108. [Google Scholar] [CrossRef] [PubMed]
  6. Lassalle, M.; Chastang, J.F.; Niedhammer, I. Working conditions and psychotropic drug use: Cross-sectional and prospective results from the French national SIP study. J. Psychiatr. Res. 2015, 63, 50–57. [Google Scholar] [CrossRef] [PubMed]
  7. Hoven, H.; Wahrendorf, M.; Siegrist, J. Occupational position, work stress and depressive symptoms: A pathway analysis of longitudinal SHARE data. J. Epidemiol. Community Health 2015. [Google Scholar] [CrossRef] [PubMed]
  8. Butterworth, P.; Olesen, S.C.; Leach, L.S. Socioeconomic differences in antidepressant use in the PATH Through Life Study: Evidence of health inequalities, prescribing bias, or an effective social safety net? J. Affect. Disord. 2013, 149, 75–83. [Google Scholar] [CrossRef] [PubMed]
  9. Von Soest, T.; Bramness, J.G.; Pedersen, W.; Wichstrøm, L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. Epidemiol. Psychiatr. Sci. 2012, 21, 87–95. [Google Scholar] [CrossRef] [PubMed]
  10. Rubio-Valera, M.; Fernández, A.; Luciano, J.V.; Hughes, C.M.; Pinto-Meza, A.; Moreno-Küstner, B.; Palao, D.J.; Haro, J.M.; Serrano-Blanco, A. Psychotropic prescribing in Catalonia: Results from an epidemiological study. Fam. Pract. 2012, 29, 154–162. [Google Scholar] [CrossRef] [PubMed]
  11. Crump, C.; Sundquist, K.; Sundquist, J.; Winkleby, M.A. Neighborhood deprivation and psychiatric medication prescription: A Swedish national multilevel study. Ann. Epidemiol. 2011, 21, 231–237. [Google Scholar] [CrossRef] [PubMed]
  12. Tsimtsiou, Z.; Ashworth, M.; Jones, R. Variations in anxiolytic and hypnotic prescribing by GPs: A cross-sectional analysis using data from the UK Quality and Outcomes Framework. Br. J. Gen. Pract. 2009, 59, e191–e198. [Google Scholar] [CrossRef] [PubMed]
  13. Codony, M.; Alonso, J.; Almansa, J.; Vilagut, G.; Domingo, A.; Pinto-Meza, A.; Fernández, A.; Serrano-Blanco, A.; Márquez, M.; Haro, J.M. Psychotropic medications use in Spain. Results of the ESEMeD-Spain study. Actas Esp. Psiquiatr. 2007, 35, 29–36. [Google Scholar] [PubMed]
  14. Wang, P.S.; Lane, M.; Olfson, M.; Pincus, H.A.; Wells, K.B.; Kessler, R.C. Twelve month use of mental health services in the U.S. Results from the National Comorbidity Survey Replication (NCS-R). Arch. Gen. Psychiatry 2005, 62, 629–640. [Google Scholar] [CrossRef] [PubMed]
  15. Lesén, E.; Andersson, K.; Petzold, M.; Carlsten, A. Socioeconomic determinants of psychotropic drug utilization among elderly: A national population-based cross-sectional study. BMC Public Health 2010, 10, 118. [Google Scholar] [CrossRef] [PubMed]
  16. Encuesta Nacional de Salud 2006. Available online: http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2006/metodENS2006.pdf (accessed on 20 May 2015).
  17. Encuesta Nacional de Salud de España 2011/2012. Available online: http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/encuesta2011.htm (accessed on 20 May 2015).
  18. Athanasopoulos, C.; Pitychoutis, P.M.; Messari, I.; Lionis, C.; Papadopoulou-Daifoti, Z. Is drug utilization in Greece sex dependent? A population-based study. Basic Clin. Pharmacol. Toxicol. 2013, 112, 55–62. [Google Scholar] [CrossRef] [PubMed]
  19. Ilyas, S.; Moncrieff, J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. Br. J. Psychiatry 2012, 200, 393–398. [Google Scholar] [CrossRef] [PubMed]
  20. Abbing-Karahagopian, V.; Huerta, C.; Souverein, P.C.; de Abajo, F.; Leufkens, H.G.; Slattery, J.; Alvarez, Y.; Miret, M.; Gil, M.; Oliva, B.; et al. Antidepressant prescribing in five European countries: Application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur. J. Clin. Pharmacol. 2014, 70, 849–857. [Google Scholar] [CrossRef] [PubMed]
  21. Mojtabai, R.; Olfson, M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 2010, 67, 26–36. [Google Scholar] [CrossRef] [PubMed]
  22. Meng, X.; D’Arcy, C.; Tempier, R. Trends in psychotropic use in Saskatchewan from 1983 to 2007. Can. J. Psychiatry 2013, 58, 426–431. [Google Scholar] [PubMed]
  23. Manteuffel, M.; Williams, S.; Chen, W.; Verbrugge, R.R.; Pittman, D.G.; Steinkellner, A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J. Women’s Health 2014, 23, 112–119. [Google Scholar] [CrossRef] [PubMed]
  24. Vicente Sánchez, M.P.; Macías Saint-Gerons, D.; de la Fuente Honrubia, C.; González Bermejo, D.; Montero Corominas, D.; Catalá-López, F. Trends of use of anxiolytics and hypnotics in Spain from 2000 to 2011. Rev. Esp. Salud Publica 2013, 87, 247–255. [Google Scholar] [CrossRef] [PubMed]
  25. Takayanagi, Y.; Spira, A.P.; Bienvenu, O.J.; Hock, R.S.; Carras, M.C.; Eaton, W.W.; Mojtabai, R. Antidepressant use and lifetime history of mental disorders in a community sample: Results from the Baltimore Epidemiologic Catchment Area Study. J. Clin. Psychiatry 2015, 76, 40–44. [Google Scholar] [CrossRef] [PubMed]
  26. Rundberg, J.; Lidfeldt, J.; Nerbrand, C.; Samsioe, G.; Romelsjö, A.; Ojehagen, A. Few middle-aged women with severe mental symptoms use psychotropic drugs: The Women’s Health in Lund Area (WHILA) Study. Scand. J. Public Health 2005, 33, 384–391. [Google Scholar] [CrossRef] [PubMed]
  27. Strandh, M.; Hammarström, A.; Nilsson, K.; Nordenmark, M.; Russel, H. Unemployment, gender and mental health: The role of the gender regime. Soc. Health Illn. 2013, 35, 649–665. [Google Scholar] [CrossRef] [PubMed]
  28. Bradford, W.D.; Lastrapes, W.D. A prescription for unemployment? Recessions and the demand for mental health drugs. Health Econ. 2014, 23, 1301–1325. [Google Scholar] [CrossRef] [PubMed]
  29. Wise, J. One in 10 women in England takes antidepressants, survey shows. BMJ 2014, 14, g7641. [Google Scholar] [CrossRef] [PubMed]
  30. Rikala, M.; Korhonen, M.J.; Sulkava, R.; Hartikainen, S. Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users. Eur. J. Clin. Pharmacol. 2011, 67, 731–739. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Anxiolytics and antidepressant drug used in Spanish adult population. Spanish National Health Surveys (SNHS) 2006 and 2012 (Percentage and 95% Confidence Intervals).
Table 1. Anxiolytics and antidepressant drug used in Spanish adult population. Spanish National Health Surveys (SNHS) 2006 and 2012 (Percentage and 95% Confidence Intervals).
Psychotropic DrugsFemale †Male ǂ
Anxiolytics SNHS 200615.69 (14.98–16.42)7.32 (6.71–7.98)
Anxiolytics SNHS 201216.79 (15.97–17.63)7.51 (6.87–8.19)
Antidepressant SNHS 20068.89 (8.34–9.47)3.58 (3.14–4.07)
Antidepressant SNHS 20127.47 (6.92–8.05)1.82 (1.55–2.20)
† Statistically significant differences (p < 0.05) in women SNHS 2006–SNHS 2012; ǂ Statistically significant differences (p < 0.05) in men SNHS 2006–SNHS 2012.
Table
Table 2. Prevalence of psychotropic drug use in adult residents in Spain according to sociodemographic variables, lifestyle; health profile and healthcare resources. Spanish National Health Surveys 2006 and 2012.
Table 2. Prevalence of psychotropic drug use in adult residents in Spain according to sociodemographic variables, lifestyle; health profile and healthcare resources. Spanish National Health Surveys 2006 and 2012.
VariablesCategoriesWomenMen
SNHS 2006 % (95% CI)SNHS 2012 % (95% CI)SNHS 2006 % (95% CI)SNHS 2012 % (95% CI)
Age * + ** ++25–44 †9.1 (8.2–10.1)7.7 (6.7–8.8)5.0 (4.2–5.9)4.8 (3.9–5.8)
45–64 †21.8 (20.4–23.3)19.3 (17.8–20.8)9.7 (8.5–11.1)8.5 (7.4–9.7)
65 or more32.6 (30.8–34.4)33.3 (31.5–35.3)16.1 (14.4–17.9)14.5 (12.9–16.3)
Nationality * + ** ++Spanish20.1 (19.3–20.9)19.4 (18.5–20.3)9.4 (8.7–10.2)8.5 (7.8–9.2)
Immigrants ǂ10.5 (8.2–13.4)8.4 (6.1–11.4)2.2 (1.3–3.8)4.9 (2.9–8.0)
Marital status * + ** ++Not Married22.3 (20.8–23.7)21.0 (19.6–22.4)9.9 (8.5–11.4)8.2 (7.1–9.5)
Married †17.7 (16.8–18.7)16.2 (15.2–17.3)8.3 (7.5–9.1)8.0 (7.2–8.9)
Occupational status * + ** ++Employed11.5 (10.5–12.6)8.3 (7.4–9.4)4.5 (3.9–5.2)4.4 (3.8–5.2)
Unemployed13.7 (11.3–16.5)14.9 (12.6–17.6)9.9 (7.0–13.8)5.8 (4.4–7.6)
Inactive †25.9 (24.7–27.1)28.2 (26.7–29.6)18.1 (16.5–20.0)16.4 (14.8–18.1)
Social class * ** ++High13.6 (12.1–15.3)14.5 (12.7–16.5)7.9 (6.6–9.5)6.6 (5.4–8.1)
Middle †19.1 (18.0–20.3)16.9 (15.5–18.4)9.1 (8.2–10.1)7.1 (6.1–8.3)
Low21.9 (20.4–23.6)19.9 (18.6–21.3)8.3 (7.1–9.8)9.2 (8.2–10.4)
Educational level * + ** ++No formal education33.3 (31.0–35.7)31.7 (29.3–34.2)14.1 (11.7–16.8)13.6 (11.2–16.3)
Junior school †23.7 (22.2–25.1)27.8 (25.1–30.7)9.6 (8.4–10.9)13.1 (10.8–16.0)
High school †13.3 (12.1–14.7)16.3 (15.1–17.5)8.1 (6.9–9.4)7.5 (6.7–8.5)
University10.0 (8.76–11.4)8.8 (7.5–10.3)6.5 (5.4–7.8)4.6 (3.7–5.7)
Monthly income * + ** ++900 €28.4 (26.7–30.2)26.2 (24.4–28.0)14.7 (12.9–16.7)12.3 (10.6–14.1)
901–1800 €18.4 (17.1–19.6)16.7 (15.1–18.5)8.1 (7.2–9.3)8.3 (7.1–9.8)
more than 1800 €11.2 (9.9–12.7)12.2 (10.6–13.9)6.1 (5.1–7.3)5.3 (4.3–6.4)
Smoking habit * **Non smoker20.0 (19.1–21.0)19.0 (18.0–20.0)8.6 (7.9–9.5)8.5 (7.7–9.4)
Smoker15.5 (14.0–17.1)15.3 (13.5–17.2)8.8 (7.6–10.1)7.2 (6.1–8.4)
Alcohol consumption * + ** ++No21.7 (20.7–22.8)21.4 (20.3–22.6)13.5 (11.9–15.2)12.1 (10.8–13.6)
Yes †15.1 (14.0–16.3)12.6 (11.5–13.9)6.8 (6.1–7.5)5.9 (5.2–6.7)
Physical activity * ** ++Yes †18.1 (17.1–19.2)14.9 (13.9–16.1)8.3 (7.5–9.2)6.6 (5.8–7.5)
No20.2 (19.0–21.4)21.4 (20.1–22.7)9.3 (8.2–10.5)10.2 (9.1–11.4)
Body mass index Kg/sq.m * + ** ++<2513.9 (12.9–15.0)13.0 (11.9–14.2)7.7 (6.7–8.9)6.9 (5.8–8.1)
25–2921.1 (19.6–22.7)19.3 (17.7–21.0)8.2 (7.3–9.2)7.5 (6.6–8.6)
30 or more25.8 (23.5–28.3)25.7 (23.4–28.4)10.4 (8.5–12.6)10.1 (8.6–11.9)
Presence of chronic disease * ** ++No5.4 (4.5–6.6)4.3 (3.5–5.4)2.8 (2.2–3.6)3.6 (2.8–4.7)
Yes22.8 (21.9–23.8)23.2 (22.1–24.3)11.8 (10.8–12.8)10.8 (9.9–11.7)
Other non-psychotropic drugs * + ** ++No †7.5 (6.5–8.6)5.8 (4.9–6.8)3.5 (2.8–4.3)2.8 (2.3–3.4)
Yes †23.0 (22.1–24.0)25.0 (23.8–26.2)12.3 (11.3–13.4)13.2 (12.1–14.5)
Medical consultation * + ** ++No †107 (9.9–11.6)12.8 (11.9–13.7)4.2 (3.6–4.8)5.3 (4.6–6.0)
Yes28.8 (27.5–30.1)28.7 (27.0–30.4)17.4 (15.9–19.1)16.6 (14.9–18.5)
Self-assessment of health status * + ** ++Very good/Good †7.9 (7.3–8.7)7.9 (7.2–87)3.6 (3.0–4.1)3.9 (3.3–4.5)
Fair/Poor/Very poor34.1 (32.6–35.6)37.0 (34.9–38.5)20.6 (18.9–22.4)20.2 (18.3–22.2)
Statistically significant differences (p < 0.05) in women: * SNHS 2006; ** SNHS 2012; † SNHS 2006–SNHS 2012; Statistically significant differences (p < 0.05) in men: + SNHS 2006; ++ SNHS 2012; ǂ SNHS 2006–SNHS 2012.
Table
Table 3. Multivariate models for associations between psychotropic drugs use and sociodemographic variables, lifestyle, health profile and healthcare resources. Spanish National Health Surveys 2006 and 2012.
Table 3. Multivariate models for associations between psychotropic drugs use and sociodemographic variables, lifestyle, health profile and healthcare resources. Spanish National Health Surveys 2006 and 2012.
VariablesWomenMen
SNHS 2006AOR (95% CI)SNHS 2012 AOR (95% CI)SNHS 2006AOR (95% CI)SNHS 2012 AOR (95% CI)
Age25–441111
45–641.91 (1.62–2.26)1.89 (1.55–2.30)1.02 (0.77–1.35)1.07 (0.80–1.45)
65 or more1.96 (1.59–2.42)1.85 (1.43–2.40)0.67 (0.46–0.97)0.55 (0.36–0.83)
NationalityImmigrants1111
Spanish1.51 (1.09–2.10)1.69 (1.15–2.49)2.89 (1.55–5.40)N.S.
Marital statusMarried1111
Not MarriedN.S.1.37 (1.20–1.58)1.27 (1.04–1.57)1.28 (1.04–1.58)
Occupational statusEmployed1111
Unemployed0.93 (0.71–1.21)1.60 (1.24–2.07)1.77 (1.14–2.73)1.10 (0.78–1.54)
Inactive1.19 (1.01–1.42)1.88 (1.51–2.33)2.96 (2.15–4.00)2.85 (2.02–4.00)
Monthly incomeMore than 1800 €1111
901–1800 €1.30 (1.08–1.55)N.S.N.S.N.S.
900 €1.40 (1.15–1.71)N.S.N.S.N.S.
Smoking habitNot smoker1111
Smoker1.36 (1.16–1.60)1.39 (1.16–1.68)1.51 (1.22–1.87)N.S.
Alcohol consumptionYes1111
No1.16 (1.02–1.33)1.29 (1.12–1.50)1.59 (1.31–1.94)1.61 (1.32–1.96)
Presence of chronic diseaseNo1111
Yes1.84 (1.45–2.33)1.78 (1.37–2.32)1.81 (1.32–2.49)1.47 (1.08–2.00)
Other non-psychotropic drugsNo1111
Yes1.46 (1.20–1.77)3.00 (2.48–3.64)N.S.N.S.
Medical consultationNo1111
Yes2.07 (1.82–2.37)1.50 (1.31–1.71)2.32 (1.81–3.44)1.83 (1.49–2.25)
Self-assessment of health statusVery good/Good1111
Fair/Poor/Very poor3.63 (3.15–4.18)3.60 (3.12–4.17)3.84 (3.07–4.80)3.27 (2.62–4.07)
N.S.: non-significant association.

Share and Cite

MDPI and ACS Style

Carrasco-Garrido, P.; Hernández-Barrera, V.; Jiménez-Trujillo, I.; Esteban-Hernández, J.; Álvaro-Meca, A.; López-de Andrés, A.; DelBarrio-Fernández, J.L.; Jiménez-García, R. Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study. Int. J. Environ. Res. Public Health 2016, 13, 1177. https://doi.org/10.3390/ijerph13121177

AMA Style

Carrasco-Garrido P, Hernández-Barrera V, Jiménez-Trujillo I, Esteban-Hernández J, Álvaro-Meca A, López-de Andrés A, DelBarrio-Fernández JL, Jiménez-García R. Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study. International Journal of Environmental Research and Public Health. 2016; 13(12):1177. https://doi.org/10.3390/ijerph13121177

Chicago/Turabian Style

Carrasco-Garrido, Pilar, Valentín Hernández-Barrera, Isabel Jiménez-Trujillo, Jesús Esteban-Hernández, Alejandro Álvaro-Meca, Ana López-de Andrés, José Luis DelBarrio-Fernández, and Rodrigo Jiménez-García. 2016. "Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study" International Journal of Environmental Research and Public Health 13, no. 12: 1177. https://doi.org/10.3390/ijerph13121177

APA Style

Carrasco-Garrido, P., Hernández-Barrera, V., Jiménez-Trujillo, I., Esteban-Hernández, J., Álvaro-Meca, A., López-de Andrés, A., DelBarrio-Fernández, J. L., & Jiménez-García, R. (2016). Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study. International Journal of Environmental Research and Public Health, 13(12), 1177. https://doi.org/10.3390/ijerph13121177

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop